<DOC>
	<DOC>NCT01496131</DOC>
	<brief_summary>This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.</brief_summary>
	<brief_title>Tecemotide (L-BLP25) in Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Histopathologic documentation of prostate cancer confirmed at the institution of study enrollment prior to starting this study Newly diagnosed or previously untreated prostate cancer with intermediate or high risk features as defined in the protocol No evidence of metastatic disease on computed tomography (CT) / magnetic resonance imaging (MRI) or bone scans No systemic steroid use within 2 weeks prior to initiation of experimental therapy. Limited doses of systemic steroids to prevent intravenous contrast, allergic reaction or anaphylaxis (in subjects who have known contrast allergies) are allowed Eastern Cooperative Oncology Group (ECOG) performance status of 01 Human leukocyte antigen (HLA)A2 or A3 positive for immunologic monitoring Hematological and biochemical eligibility parameters as defined in the protocol No other active malignancies within the past 3 years (with the exception of nonmelanoma skin cancers or carcinoma in situ of the bladder) Willing to travel to the study center(s) for followup visits Age greater than or equal to 18 years old Able to understand and sign informed consent Must agree to use effective birth control (such as a condom) or abstinence during and for a period of 4 months after the last administration of immunotherapy No evidence of being immunocompromised by human immunodeficiency virus, a medical condition requiring systemic steroids, a medical condition requiring immunosuppressive therapy, splenectomy Active Hepatitis B or Hepatitis C Subjects should have no autoimmune diseases that have required treatment as specified in the protocol History of immunodeficiency diseases, hereditary or congenital immunodeficiencies Serious intercurrent medical illness A clinically significant cardiac disease Subjects who have received any prior therapy for prostate cancer Subjects who have known brain metastasis, or with a history of seizures, encephalitis, or multiple sclerosis Subjects receiving any other investigational agents Contraindication to biopsy such as bleeding disorders, ratio of prothrombin time to partial thromboplastin time (PT/PTT) &gt;=1.5 times the upper limit of normal, artificial heart valve Contraindication to MRI such as subjects weighing &gt;136 kilograms, allergy to magnetic resonance (MR) contrast agent, subjects with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices Contraindication to radiation therapy such as preexisting and active prostatitis or proctitis, inflammatory bowel disease or known genetic sensitivity to ionizing radiation, or history of prior radiation to the pelvis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tecemotide</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Goserelin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>